APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Platinum-based Antineoplastic

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Platinum-based Antineoplastic Market Analysis and Forecast 2026-2032

Report ID 174026670230 December 2025191 pages

Choose your research edition.

Industry ResearchPlatinum-based Antineoplastic Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Platinum-based Antineoplastic Industry Growth and Trends Forecast to 2032116 pages · $3,450 USDMarket StructureGlobal Platinum-based Antineoplastic Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Platinum-based Antineoplastic Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Platinum-based Antineoplastic Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Platinum-based Antineoplastic market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Platinum-based Antineoplastic is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Platinum-based Antineoplastic is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Platinum-based Antineoplastic is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Platinum-based Antineoplastic is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Platinum-based Antineoplastic include ChiTaiTianQing Pharmaceutical Group, Simcere Pharmaceutical, CSPC Pharmaceutical Group, Sanofi, Novartis, MSD, Roche, Pfizer and Hengrui Medicine, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Platinum-based Antineoplastic, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Platinum-based Antineoplastic, also provides the sales of main regions and countries. Of the upcoming market potential for Platinum-based Antineoplastic, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Platinum-based Antineoplastic sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Platinum-based Antineoplastic market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Platinum-based Antineoplastic sales, projected growth trends, production technology, application and end-user industry.

Platinum-based Antineoplastic Segment by Company

ChiTaiTianQing Pharmaceutical Group

Simcere Pharmaceutical

CSPC Pharmaceutical Group

Sanofi

Novartis

MSD

Roche

Pfizer

Hengrui Medicine

Hansoh Pharmaceutical Group

GSK

Bristol-Myers Squibb

Abbvie

AstraZeneca

Asta Medica GmbH

Platinum-based Antineoplastic Segment by Type

Oxaliplatin

Cycloplatin

Carboplatin

Lobaplatin

Nedaplatin

Cisplatin

Platinum-based Antineoplastic Segment by Application

Targeted Therapy

Monotherapy

Combination Therapy

Platinum-based Antineoplastic Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Platinum-based Antineoplastic market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Platinum-based Antineoplastic and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Platinum-based Antineoplastic.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Platinum-based Antineoplastic in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Platinum-based Antineoplastic manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Platinum-based Antineoplastic sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Platinum-based Antineoplastic Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Oxaliplatin Major Manufacturers Table 3. Cycloplatin Major Manufacturers Table 4. Carboplatin Major Manufacturers Table 5. Lobaplatin Major Manufacturers Table 6. Nedaplatin Major Manufacturers Table 7. Cisplatin Major Manufacturers Table 8. Global Platinum-based Antineoplastic Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 9. Targeted Therapy Major Manufacturers Table 10. Monotherapy Major Manufacturers Table 11. Combination Therapy Major Manufacturers Table 12. Platinum-based Antineoplastic Industry Trends Table 13. Platinum-based Antineoplastic Industry Drivers Table 14. Platinum-based Antineoplastic Industry Opportunities and Challenges Table 15. Platinum-based Antineoplastic Industry Restraints Table 16. Global Platinum-based Antineoplastic Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Platinum-based Antineoplastic Revenue by Region (2021-2026) & (US$ Million) Table 18. Global Platinum-based Antineoplastic Revenue by Region (2027-2032) & (US$ Million) Table 19. Global Platinum-based Antineoplastic Revenue Market Share by Region (2021-2026) Table 20. Global Platinum-based Antineoplastic Revenue Market Share by Region (2027-2032) Table 21. Global Platinum-based Antineoplastic Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (Units) Table 22. Global Platinum-based Antineoplastic Sales by Region (2021-2026) & (Units) Table 23. Global Platinum-based Antineoplastic Sales by Region (2027-2032) & (Units) Table 24. Global Platinum-based Antineoplastic Sales Market Share by Region (2021-2026) Table 25. Global Platinum-based Antineoplastic Sales Market Share by Region (2027-2032) Table 26. Global Platinum-based Antineoplastic Revenue by Manufacturers (US$ Million) & (2021-2026) Table 27. Global Platinum-based Antineoplastic Revenue Market Share by Manufacturers (2021-2026) Table 28. Global Platinum-based Antineoplastic Sales by Manufacturers (US$ Million) & (2021-2026) Table 29. Global Platinum-based Antineoplastic Sales Market Share by Manufacturers (2021-2026) Table 30. Global Platinum-based Antineoplastic Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 31. Global Platinum-based Antineoplastic Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 32. Global Platinum-based Antineoplastic Key Manufacturers Manufacturing Sites & Headquarters Table 33. Global Platinum-based Antineoplastic Manufacturers, Product Type & Application Table 34. Global Platinum-based Antineoplastic Manufacturers' Establishment Date Table 35. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 36. Global Platinum-based Antineoplastic by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 37. Global Platinum-based Antineoplastic Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Platinum-based Antineoplastic Revenue by Type (2021-2026) & (US$ Million) Table 39. Global Platinum-based Antineoplastic Revenue by Type (2027-2032) & (US$ Million) Table 40. Global Platinum-based Antineoplastic Revenue Market Share by Type (2021-2026) Table 41. Global Platinum-based Antineoplastic Revenue Market Share by Type (2027-2032) Table 42. Global Platinum-based Antineoplastic Sales by Type 2021 VS 2025 VS 2032 (Units) Table 43. Global Platinum-based Antineoplastic Sales by Type (2021-2026) & (Units) Table 44. Global Platinum-based Antineoplastic Sales by Type (2027-2032) & (Units) Table 45. Global Platinum-based Antineoplastic Sales Market Share by Type (2021-2026) Table 46. Global Platinum-based Antineoplastic Sales Market Share by Type (2027-2032) Table 47. Global Platinum-based Antineoplastic Price by Type (2021-2026) & (US$/Unit) Table 48. Global Platinum-based Antineoplastic Price by Type (2027-2032) & (US$/Unit) Table 49. Global Platinum-based Antineoplastic Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Platinum-based Antineoplastic Revenue by Application (2021-2026) & (US$ Million) Table 51. Global Platinum-based Antineoplastic Revenue by Application (2027-2032) & (US$ Million) Table 52. Global Platinum-based Antineoplastic Revenue Market Share by Application (2021-2026) Table 53. Global Platinum-based Antineoplastic Revenue Market Share by Application (2027-2032) Table 54. Global Platinum-based Antineoplastic Sales by Application 2021 VS 2025 VS 2032 (Units) Table 55. Global Platinum-based Antineoplastic Sales by Application (2021-2026) & (Units) Table 56. Global Platinum-based Antineoplastic Sales by Application (2027-2032) & (Units) Table 57. Global Platinum-based Antineoplastic Sales Market Share by Application (2021-2026) Table 58. Global Platinum-based Antineoplastic Sales Market Share by Application (2027-2032) Table 59. Global Platinum-based Antineoplastic Price by Application (2021-2026) & (US$/Unit) Table 60. Global Platinum-based Antineoplastic Price by Application (2027-2032) & (US$/Unit) Table 61. ChiTaiTianQing Pharmaceutical Group Company Information Table 62. ChiTaiTianQing Pharmaceutical Group Business Overview Table 63. ChiTaiTianQing Pharmaceutical Group Platinum-based Antineoplastic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 64. ChiTaiTianQing Pharmaceutical Group Platinum-based Antineoplastic Product Portfolio Table 65. ChiTaiTianQing Pharmaceutical Group Recent Development Table 66. Simcere Pharmaceutical Company Information Table 67. Simcere Pharmaceutical Business Overview Table 68. Simcere Pharmaceutical Platinum-based Antineoplastic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Simcere Pharmaceutical Platinum-based Antineoplastic Product Portfolio Table 70. Simcere Pharmaceutical Recent Development Table 71. CSPC Pharmaceutical Group Company Information Table 72. CSPC Pharmaceutical Group Business Overview Table 73. CSPC Pharmaceutical Group Platinum-based Antineoplastic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. CSPC Pharmaceutical Group Platinum-based Antineoplastic Product Portfolio Table 75. CSPC Pharmaceutical Group Recent Development Table 76. Sanofi Company Information Table 77. Sanofi Business Overview Table 78. Sanofi Platinum-based Antineoplastic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Sanofi Platinum-based Antineoplastic Product Portfolio Table 80. Sanofi Recent Development Table 81. Novartis Company Information Table 82. Novartis Business Overview Table 83. Novartis Platinum-based Antineoplastic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Novartis Platinum-based Antineoplastic Product Portfolio Table 85. Novartis Recent Development Table 86. MSD Company Information Table 87. MSD Business Overview Table 88. MSD Platinum-based Antineoplastic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. MSD Platinum-based Antineoplastic Product Portfolio Table 90. MSD Recent Development Table 91. Roche Company Information Table 92. Roche Business Overview Table 93. Roche Platinum-based Antineoplastic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Roche Platinum-based Antineoplastic Product Portfolio Table 95. Roche Recent Development Table 96. Pfizer Company Information Table 97. Pfizer Business Overview Table 98. Pfizer Platinum-based Antineoplastic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Pfizer Platinum-based Antineoplastic Product Portfolio Table 100. Pfizer Recent Development Table 101. Hengrui Medicine Company Information Table 102. Hengrui Medicine Business Overview Table 103. Hengrui Medicine Platinum-based Antineoplastic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Hengrui Medicine Platinum-based Antineoplastic Product Portfolio Table 105. Hengrui Medicine Recent Development Table 106. Hansoh Pharmaceutical Group Company Information Table 107. Hansoh Pharmaceutical Group Business Overview Table 108. Hansoh Pharmaceutical Group Platinum-based Antineoplastic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Hansoh Pharmaceutical Group Platinum-based Antineoplastic Product Portfolio Table 110. Hansoh Pharmaceutical Group Recent Development Table 111. GSK Company Information Table 112. GSK Business Overview Table 113. GSK Platinum-based Antineoplastic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. GSK Platinum-based Antineoplastic Product Portfolio Table 115. GSK Recent Development Table 116. Bristol-Myers Squibb Company Information Table 117. Bristol-Myers Squibb Business Overview Table 118. Bristol-Myers Squibb Platinum-based Antineoplastic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Bristol-Myers Squibb Platinum-based Antineoplastic Product Portfolio Table 120. Bristol-Myers Squibb Recent Development Table 121. Abbvie Company Information Table 122. Abbvie Business Overview Table 123. Abbvie Platinum-based Antineoplastic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Abbvie Platinum-based Antineoplastic Product Portfolio Table 125. Abbvie Recent Development Table 126. AstraZeneca Company Information Table 127. AstraZeneca Business Overview Table 128. AstraZeneca Platinum-based Antineoplastic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. AstraZeneca Platinum-based Antineoplastic Product Portfolio Table 130. AstraZeneca Recent Development Table 131. Asta Medica GmbH Company Information Table 132. Asta Medica GmbH Business Overview Table 133. Asta Medica GmbH Platinum-based Antineoplastic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. Asta Medica GmbH Platinum-based Antineoplastic Product Portfolio Table 135. Asta Medica GmbH Recent Development Table 136. North America Platinum-based Antineoplastic Revenue by Type (2021-2026) & (US$ Million) Table 137. North America Platinum-based Antineoplastic Revenue by Type (2027-2032) & (US$ Million) Table 138. North America Platinum-based Antineoplastic Sales by Type (2021-2026) & (Units) Table 139. North America Platinum-based Antineoplastic Sales by Type (2027-2032) & (Units) Table 140. North America Platinum-based Antineoplastic Sales Price by Type (2021-2026) & (US$/Unit) Table 141. North America Platinum-based Antineoplastic Sales Price by Type (2027-2032) & (US$/Unit) Table 142. North America Platinum-based Antineoplastic Revenue by Application (2021-2026) & (US$ Million) Table 143. North America Platinum-based Antineoplastic Revenue by Application (2027-2032) & (US$ Million) Table 144. North America Platinum-based Antineoplastic Sales by Application (2021-2026) & (Units) Table 145. North America Platinum-based Antineoplastic Sales by Application (2027-2032) & (Units) Table 146. North America Platinum-based Antineoplastic Sales Price by Application (2021-2026) & (US$/Unit) Table 147. North America Platinum-based Antineoplastic Sales Price by Application (2027-2032) & (US$/Unit) Table 148. North America Platinum-based Antineoplastic Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 149. North America Platinum-based Antineoplastic Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 150. North America Platinum-based Antineoplastic Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 151. North America Platinum-based Antineoplastic Sales by Country (2021 VS 2025 VS 2032) & (Units) Table 152. North America Platinum-based Antineoplastic Sales by Country (2021-2026) & (Units) Table 153. North America Platinum-based Antineoplastic Sales by Country (2027-2032) & (Units) Table 154. North America Platinum-based Antineoplastic Sales Price by Country (2021-2026) & (US$/Unit) Table 155. North America Platinum-based Antineoplastic Sales Price by Country (2027-2032) & (US$/Unit) Table 156. United States Platinum-based Antineoplastic Revenue (2021-2032) & (US$ Million) Table 157. Canada Platinum-based Antineoplastic Revenue (2021-2032) & (US$ Million) Table 158. Europe Platinum-based Antineoplastic Revenue by Type (2021-2026) & (US$ Million) Table 159. Europe Platinum-based Antineoplastic Revenue by Type (2027-2032) & (US$ Million) Table 160. Europe Platinum-based Antineoplastic Sales by Type (2021-2026) & (Units) Table 161. Europe Platinum-based Antineoplastic Sales by Type (2027-2032) & (Units) Table 162. Europe Platinum-based Antineoplastic Sales Price by Type (2021-2026) & (US$/Unit) Table 163. Europe Platinum-based Antineoplastic Sales Price by Type (2027-2032) & (US$/Unit) Table 164. Europe Platinum-based Antineoplastic Revenue by Application (2021-2026) & (US$ Million) Table 165. Europe Platinum-based Antineoplastic Revenue by Application (2027-2032) & (US$ Million) Table 166. Europe Platinum-based Antineoplastic Sales by Application (2021-2026) & (Units) Table 167. Europe Platinum-based Antineoplastic Sales by Application (2027-2032) & (Units) Table 168. Europe Platinum-based Antineoplastic Sales Price by Application (2021-2026) & (US$/Unit) Table 169. Europe Platinum-based Antineoplastic Sales Price by Application (2027-2032) & (US$/Unit) Table 170. Europe Platinum-based Antineoplastic Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 171. Europe Platinum-based Antineoplastic Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 172. Europe Platinum-based Antineoplastic Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 173. Europe Platinum-based Antineoplastic Sales by Country (2021 VS 2025 VS 2032) & (Units) Table 174. Europe Platinum-based Antineoplastic Sales by Country (2021-2026) & (Units) Table 175. Europe Platinum-based Antineoplastic Sales by Country (2027-2032) & (Units) Table 176. Europe Platinum-based Antineoplastic Sales Price by Country (2021-2026) & (US$/Unit) Table 177. Europe Platinum-based Antineoplastic Sales Price by Country (2027-2032) & (US$/Unit) Table 178. Germany Platinum-based Antineoplastic Revenue (2021-2032) & (US$ Million) Table 179. France Platinum-based Antineoplastic Revenue (2021-2032) & (US$ Million) Table 180. U.K. Platinum-based Antineoplastic Revenue (2021-2032) & (US$ Million) Table 181. Italy Platinum-based Antineoplastic Revenue (2021-2032) & (US$ Million) Table 182. Netherlands Platinum-based Antineoplastic Revenue (2021-2032) & (US$ Million) Table 183. China Platinum-based Antineoplastic Revenue by Type (2021-2026) & (US$ Million) Table 184. China Platinum-based Antineoplastic Revenue by Type (2027-2032) & (US$ Million) Table 185. China Platinum-based Antineoplastic Sales by Type (2021-2026) & (Units) Table 186. China Platinum-based Antineoplastic Sales by Type (2027-2032) & (Units) Table 187. China Platinum-based Antineoplastic Sales Price by Type (2021-2026) & (US$/Unit) Table 188. China Platinum-based Antineoplastic Sales Price by Type (2027-2032) & (US$/Unit) Table 189. China Platinum-based Antineoplastic Revenue by Application (2021-2026) & (US$ Million) Table 190. China Platinum-based Antineoplastic Revenue by Application (2027-2032) & (US$ Million) Table 191. China Platinum-based Antineoplastic Sales by Application (2021-2026) & (Units) Table 192. China Platinum-based Antineoplastic Sales by Application (2027-2032) & (Units) Table 193. China Platinum-based Antineoplastic Sales Price by Application (2021-2026) & (US$/Unit) Table 194. China Platinum-based Antineoplastic Sales Price by Application (2027-2032) & (US$/Unit) Table 195. Asia Platinum-based Antineoplastic Revenue by Type (2021-2026) & (US$ Million) Table 196. Asia Platinum-based Antineoplastic Revenue by Type (2027-2032) & (US$ Million) Table 197. Asia Platinum-based Antineoplastic Sales by Type (2021-2026) & (Units) Table 198. Asia Platinum-based Antineoplastic Sales by Type (2027-2032) & (Units) Table 199. Asia Platinum-based Antineoplastic Sales Price by Type (2021-2026) & (US$/Unit) Table 200. Asia Platinum-based Antineoplastic Sales Price by Type (2027-2032) & (US$/Unit) Table 201. Asia Platinum-based Antineoplastic Revenue by Application (2021-2026) & (US$ Million) Table 202. Asia Platinum-based Antineoplastic Revenue by Application (2027-2032) & (US$ Million) Table 203. Asia Platinum-based Antineoplastic Sales by Application (2021-2026) & (Units) Table 204. Asia Platinum-based Antineoplastic Sales by Application (2027-2032) & (Units) Table 205. Asia Platinum-based Antineoplastic Sales Price by Application (2021-2026) & (US$/Unit) Table 206. Asia Platinum-based Antineoplastic Sales Price by Application (2027-2032) & (US$/Unit) Table 207. Asia Platinum-based Antineoplastic Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 208. Asia Platinum-based Antineoplastic Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 209. Asia Platinum-based Antineoplastic Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 210. Asia Platinum-based Antineoplastic Sales by Country (2021 VS 2025 VS 2032) & (Units) Table 211. Asia Platinum-based Antineoplastic Sales by Country (2021-2026) & (Units) Table 212. Asia Platinum-based Antineoplastic Sales by Country (2027-2032) & (Units) Table 213. Asia Platinum-based Antineoplastic Sales Price by Country (2021-2026) & (US$/Unit) Table 214. Asia Platinum-based Antineoplastic Sales Price by Country (2027-2032) & (US$/Unit) Table 215. Japan Platinum-based Antineoplastic Revenue (2021-2032) & (US$ Million) Table 216. South Korea Platinum-based Antineoplastic Revenue (2021-2032) & (US$ Million) Table 217. India Platinum-based Antineoplastic Revenue (2021-2032) & (US$ Million) Table 218. Australia Platinum-based Antineoplastic Revenue (2021-2032) & (US$ Million) Table 219. China Taiwan Platinum-based Antineoplastic Revenue (2021-2032) & (US$ Million) Table 220. Southeast Asia Platinum-based Antineoplastic Revenue (2021-2032) & (US$ Million) Table 221. SAMEA Platinum-based Antineoplastic Revenue by Type (2021-2026) & (US$ Million) Table 222. SAMEA Platinum-based Antineoplastic Revenue by Type (2027-2032) & (US$ Million) Table 223. SAMEA Platinum-based Antineoplastic Sales by Type (2021-2026) & (Units) Table 224. SAMEA Platinum-based Antineoplastic Sales by Type (2027-2032) & (Units) Table 225. SAMEA Platinum-based Antineoplastic Sales Price by Type (2021-2026) & (US$/Unit) Table 226. SAMEA Platinum-based Antineoplastic Sales Price by Type (2027-2032) & (US$/Unit) Table 227. SAMEA Platinum-based Antineoplastic Revenue by Application (2021-2026) & (US$ Million) Table 228. SAMEA Platinum-based Antineoplastic Revenue by Application (2027-2032) & (US$ Million) Table 229. SAMEA Platinum-based Antineoplastic Sales by Application (2021-2026) & (Units) Table 230. SAMEA Platinum-based Antineoplastic Sales by Application (2027-2032) & (Units) Table 231. SAMEA Platinum-based Antineoplastic Sales Price by Application (2021-2026) & (US$/Unit) Table 232. SAMEA Platinum-based Antineoplastic Sales Price by Application (2027-2032) & (US$/Unit) Table 233. SAMEA Platinum-based Antineoplastic Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 234. SAMEA Platinum-based Antineoplastic Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 235. SAMEA Platinum-based Antineoplastic Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 236. SAMEA Platinum-based Antineoplastic Sales by Country (2021 VS 2025 VS 2032) & (Units) Table 237. SAMEA Platinum-based Antineoplastic Sales by Country (2021-2026) & (Units) Table 238. SAMEA Platinum-based Antineoplastic Sales by Country (2027-2032) & (Units) Table 239. SAMEA Platinum-based Antineoplastic Sales Price by Country (2021-2026) & (US$/Unit) Table 240. SAMEA Platinum-based Antineoplastic Sales Price by Country (2027-2032) & (US$/Unit) Table 241. Brazil Platinum-based Antineoplastic Revenue (2021-2032) & (US$ Million) Table 242. Argentina Platinum-based Antineoplastic Revenue (2021-2032) & (US$ Million) Table 243. Chile Platinum-based Antineoplastic Revenue (2021-2032) & (US$ Million) Table 244. Colombia Platinum-based Antineoplastic Revenue (2021-2032) & (US$ Million) Table 245. Peru Platinum-based Antineoplastic Revenue (2021-2032) & (US$ Million) Table 246. Saudi Arabia Platinum-based Antineoplastic Revenue (2021-2032) & (US$ Million) Table 247. Israel Platinum-based Antineoplastic Revenue (2021-2032) & (US$ Million) Table 248. UAE Platinum-based Antineoplastic Revenue (2021-2032) & (US$ Million) Table 249. Turkey Platinum-based Antineoplastic Revenue (2021-2032) & (US$ Million) Table 250. Iran Platinum-based Antineoplastic Revenue (2021-2032) & (US$ Million) Table 251. Egypt Platinum-based Antineoplastic Revenue (2021-2032) & (US$ Million) Table 252. Key Raw Materials Table 253. Raw Materials Key Suppliers Table 254. Platinum-based Antineoplastic Distributors List Table 255. Platinum-based Antineoplastic Customers List Table 256. Research Programs/Design for This Report Table 257. Authors List of This Report Table 258. Secondary Sources Table 259. Primary Sources List of Figures Figure 1. Platinum-based Antineoplastic Image Figure 2. Global Platinum-based Antineoplastic Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Platinum-based Antineoplastic Market Size Share 2021 VS 2025 VS 2032 Figure 4. Oxaliplatin Image Figure 5. Cycloplatin Image Figure 6. Carboplatin Image Figure 7. Lobaplatin Image Figure 8. Nedaplatin Image Figure 9. Cisplatin Image Figure 10. Global Platinum-based Antineoplastic Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global Platinum-based Antineoplastic Market Size Share 2021 VS 2025 VS 2032 Figure 12. Targeted Therapy Image Figure 13. Monotherapy Image Figure 14. Combination Therapy Image Figure 15. Global Platinum-based Antineoplastic Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Platinum-based Antineoplastic Revenue (2021-2032) & (US$ Million) Figure 17. Global Platinum-based Antineoplastic Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global Platinum-based Antineoplastic Revenue Market Share by Region: 2025 Versus 2032 Figure 19. Global Platinum-based Antineoplastic Revenue Market Share by Region (2021-2032) Figure 20. Global Platinum-based Antineoplastic Sales (2021-2032) & (Units) Figure 21. Global Platinum-based Antineoplastic Sales by Region: 2021 VS 2025 VS 2032 (Units) Figure 22. Global Platinum-based Antineoplastic Sales Market Share by Region (2021-2032) Figure 23. US & Canada & Mexico Platinum-based Antineoplastic Sales YoY (2021-2032) & (Units) Figure 24. Europe Platinum-based Antineoplastic Sales YoY (2021-2032) & (Units) Figure 25. China Platinum-based Antineoplastic Sales YoY (2021-2032) & (Units) Figure 26. Asia (Excluding China) Platinum-based Antineoplastic Sales YoY (2021-2032) & (Units) Figure 27. South America, Middle East and Africa Platinum-based Antineoplastic Sales YoY (2021-2032) & (Units) Figure 28. Global Platinum-based Antineoplastic Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 29. Global Platinum-based Antineoplastic Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 30. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 31. Global Platinum-based Antineoplastic Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 32. Global Platinum-based Antineoplastic Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 33. Global Platinum-based Antineoplastic Revenue Market Share by Type (2021-2032) Figure 34. Global Platinum-based Antineoplastic Sales by Type (2021 VS 2025 VS 2032) & (Units) Figure 35. Global Platinum-based Antineoplastic Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 36. Global Platinum-based Antineoplastic Sales Market Share by Type (2021-2032) Figure 37. Global Platinum-based Antineoplastic Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 38. Global Platinum-based Antineoplastic Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 39. Global Platinum-based Antineoplastic Revenue Market Share by Application (2021-2032) Figure 40. Global Platinum-based Antineoplastic Sales by Application (2021 VS 2025 VS 2032) & (Units) Figure 41. Global Platinum-based Antineoplastic Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 42. Global Platinum-based Antineoplastic Sales Market Share by Application (2021-2032) Figure 43. North America Platinum-based Antineoplastic Revenue Share by Type (2021-2032) Figure 44. North America Platinum-based Antineoplastic Sales Share by Type (2021-2032) Figure 45. North America Platinum-based Antineoplastic Revenue Share by Application (2021-2032) Figure 46. North America Platinum-based Antineoplastic Sales Share by Application (2021-2032) Figure 47. North America Platinum-based Antineoplastic Revenue Share by Country (2021-2032) Figure 48. North America Platinum-based Antineoplastic Sales Share by Country (2021-2032) Figure 49. Europe Platinum-based Antineoplastic Revenue Share by Type (2021-2032) Figure 50. Europe Platinum-based Antineoplastic Sales Share by Type (2021-2032) Figure 51. Europe Platinum-based Antineoplastic Revenue Share by Application (2021-2032) Figure 52. Europe Platinum-based Antineoplastic Sales Share by Application (2021-2032) Figure 53. Europe Platinum-based Antineoplastic Revenue Share by Country (2021-2032) Figure 54. Europe Platinum-based Antineoplastic Sales Share by Country (2021-2032) Figure 55. China Platinum-based Antineoplastic Revenue Share by Type (2021-2032) Figure 56. China Platinum-based Antineoplastic Sales Share by Type (2021-2032) Figure 57. China Platinum-based Antineoplastic Revenue Share by Application (2021-2032) Figure 58. China Platinum-based Antineoplastic Sales Share by Application (2021-2032) Figure 59. Asia Platinum-based Antineoplastic Revenue Share by Type (2021-2032) Figure 60. Asia Platinum-based Antineoplastic Sales Share by Type (2021-2032) Figure 61. Asia Platinum-based Antineoplastic Revenue Share by Application (2021-2032) Figure 62. Asia Platinum-based Antineoplastic Sales Share by Application (2021-2032) Figure 63. Asia Platinum-based Antineoplastic Revenue Share by Country (2021-2032) Figure 64. Asia Platinum-based Antineoplastic Sales Share by Country (2021-2032) Figure 65. SAMEA Platinum-based Antineoplastic Revenue Share by Type (2021-2032) Figure 66. SAMEA Platinum-based Antineoplastic Sales Share by Type (2021-2032) Figure 67. SAMEA Platinum-based Antineoplastic Revenue Share by Application (2021-2032) Figure 68. SAMEA Platinum-based Antineoplastic Sales Share by Application (2021-2032) Figure 69. SAMEA Platinum-based Antineoplastic Revenue Share by Country (2021-2032) Figure 70. SAMEA Platinum-based Antineoplastic Sales Share by Country (2021-2032) Figure 71. Platinum-based Antineoplastic Value Chain Figure 72. Manufacturing Cost Structure Figure 73. Platinum-based Antineoplastic Production Mode & Process Figure 74. Direct Comparison with Distribution Share Figure 75. Distributors Profiles Figure 76. Years Considered Figure 77. Research Process Figure 78. Key Executives Interviewed

Scope & coverage.

Types
  • Oxaliplatin
  • Cycloplatin
  • Carboplatin
  • Lobaplatin
  • Nedaplatin
  • Cisplatin
Applications
  • Targeted Therapy
  • Monotherapy
  • Combination Therapy
Companies covered
  • ChiTaiTianQing Pharmaceutical Group
  • Simcere Pharmaceutical
  • CSPC Pharmaceutical Group
  • Sanofi
  • Novartis
  • MSD
  • Roche
  • Pfizer
  • Hengrui Medicine
  • Hansoh Pharmaceutical Group
  • GSK
  • Bristol-Myers Squibb
  • Abbvie
  • AstraZeneca
  • Asta Medica GmbH

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Platinum-based Antineoplastic Market by Type
  3. 1.2.1 Global Platinum-based Antineoplastic Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Oxaliplatin
  5. 1.2.3 Cycloplatin
  6. 1.2.4 Carboplatin
  7. 1.2.5 Lobaplatin
  8. 1.2.6 Nedaplatin
  9. 1.2.7 Cisplatin
  10. 1.3 Platinum-based Antineoplastic Market by Application
  11. 1.3.1 Global Platinum-based Antineoplastic Market Size by Application, 2021 VS 2025 VS 2032
  12. 1.3.2 Targeted Therapy
  13. 1.3.3 Monotherapy
  14. 1.3.4 Combination Therapy
  15. 1.4 Assumptions and Limitations
  16. 1.5 Study Goals and Objectives
2 Platinum-based Antineoplastic Market Dynamics
  1. 2.1 Platinum-based Antineoplastic Industry Trends
  2. 2.2 Platinum-based Antineoplastic Industry Drivers
  3. 2.3 Platinum-based Antineoplastic Industry Opportunities and Challenges
  4. 2.4 Platinum-based Antineoplastic Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Platinum-based Antineoplastic Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Platinum-based Antineoplastic Revenue by Region
  3. 3.2.1 Global Platinum-based Antineoplastic Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Platinum-based Antineoplastic Revenue by Region (2021-2026)
  5. 3.2.3 Global Platinum-based Antineoplastic Revenue by Region (2027-2032)
  6. 3.2.4 Global Platinum-based Antineoplastic Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Platinum-based Antineoplastic Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Platinum-based Antineoplastic Sales by Region
  9. 3.4.1 Global Platinum-based Antineoplastic Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Platinum-based Antineoplastic Sales by Region (2021-2026)
  11. 3.4.3 Global Platinum-based Antineoplastic Sales by Region (2027-2032)
  12. 3.4.4 Global Platinum-based Antineoplastic Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Platinum-based Antineoplastic Revenue by Manufacturers
  2. 4.1.1 Global Platinum-based Antineoplastic Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Platinum-based Antineoplastic Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Platinum-based Antineoplastic Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Platinum-based Antineoplastic Sales by Manufacturers
  6. 4.2.1 Global Platinum-based Antineoplastic Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Platinum-based Antineoplastic Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Platinum-based Antineoplastic Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Platinum-based Antineoplastic Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Platinum-based Antineoplastic Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Platinum-based Antineoplastic Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Platinum-based Antineoplastic Manufacturers, Product Type & Application
  13. 4.7 Global Platinum-based Antineoplastic Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Platinum-based Antineoplastic Market CR5 and HHI
  16. 4.8.2 2025 Platinum-based Antineoplastic Tier 1, Tier 2, and Tier 3
5 Platinum-based Antineoplastic Market by Type
  1. 5.1 Global Platinum-based Antineoplastic Revenue by Type
  2. 5.1.1 Global Platinum-based Antineoplastic Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Platinum-based Antineoplastic Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Platinum-based Antineoplastic Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Platinum-based Antineoplastic Sales by Type
  6. 5.2.1 Global Platinum-based Antineoplastic Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Platinum-based Antineoplastic Sales by Type (2021-2032) & (Units)
  8. 5.2.3 Global Platinum-based Antineoplastic Sales Market Share by Type (2021-2032)
  9. 5.3 Global Platinum-based Antineoplastic Price by Type
6 Platinum-based Antineoplastic Market by Application
  1. 6.1 Global Platinum-based Antineoplastic Revenue by Application
  2. 6.1.1 Global Platinum-based Antineoplastic Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Platinum-based Antineoplastic Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Platinum-based Antineoplastic Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Platinum-based Antineoplastic Sales by Application
  6. 6.2.1 Global Platinum-based Antineoplastic Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Platinum-based Antineoplastic Sales by Application (2021-2032) & (Units)
  8. 6.2.3 Global Platinum-based Antineoplastic Sales Market Share by Application (2021-2032)
  9. 6.3 Global Platinum-based Antineoplastic Price by Application
7 Company Profiles
  1. 7.1 ChiTaiTianQing Pharmaceutical Group
  2. 7.1.1 ChiTaiTianQing Pharmaceutical Group Company Information
  3. 7.1.2 ChiTaiTianQing Pharmaceutical Group Business Overview
  4. 7.1.3 ChiTaiTianQing Pharmaceutical Group Platinum-based Antineoplastic Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 ChiTaiTianQing Pharmaceutical Group Platinum-based Antineoplastic Product Portfolio
  6. 7.1.5 ChiTaiTianQing Pharmaceutical Group Recent Developments
  7. 7.2 Simcere Pharmaceutical
  8. 7.2.1 Simcere Pharmaceutical Company Information
  9. 7.2.2 Simcere Pharmaceutical Business Overview
  10. 7.2.3 Simcere Pharmaceutical Platinum-based Antineoplastic Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Simcere Pharmaceutical Platinum-based Antineoplastic Product Portfolio
  12. 7.2.5 Simcere Pharmaceutical Recent Developments
  13. 7.3 CSPC Pharmaceutical Group
  14. 7.3.1 CSPC Pharmaceutical Group Company Information
  15. 7.3.2 CSPC Pharmaceutical Group Business Overview
  16. 7.3.3 CSPC Pharmaceutical Group Platinum-based Antineoplastic Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 CSPC Pharmaceutical Group Platinum-based Antineoplastic Product Portfolio
  18. 7.3.5 CSPC Pharmaceutical Group Recent Developments
  19. 7.4 Sanofi
  20. 7.4.1 Sanofi Company Information
  21. 7.4.2 Sanofi Business Overview
  22. 7.4.3 Sanofi Platinum-based Antineoplastic Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Sanofi Platinum-based Antineoplastic Product Portfolio
  24. 7.4.5 Sanofi Recent Developments
  25. 7.5 Novartis
  26. 7.5.1 Novartis Company Information
  27. 7.5.2 Novartis Business Overview
  28. 7.5.3 Novartis Platinum-based Antineoplastic Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Novartis Platinum-based Antineoplastic Product Portfolio
  30. 7.5.5 Novartis Recent Developments
  31. 7.6 MSD
  32. 7.6.1 MSD Company Information
  33. 7.6.2 MSD Business Overview
  34. 7.6.3 MSD Platinum-based Antineoplastic Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 MSD Platinum-based Antineoplastic Product Portfolio
  36. 7.6.5 MSD Recent Developments
  37. 7.7 Roche
  38. 7.7.1 Roche Company Information
  39. 7.7.2 Roche Business Overview
  40. 7.7.3 Roche Platinum-based Antineoplastic Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Roche Platinum-based Antineoplastic Product Portfolio
  42. 7.7.5 Roche Recent Developments
  43. 7.8 Pfizer
  44. 7.8.1 Pfizer Company Information
  45. 7.8.2 Pfizer Business Overview
  46. 7.8.3 Pfizer Platinum-based Antineoplastic Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Pfizer Platinum-based Antineoplastic Product Portfolio
  48. 7.8.5 Pfizer Recent Developments
  49. 7.9 Hengrui Medicine
  50. 7.9.1 Hengrui Medicine Company Information
  51. 7.9.2 Hengrui Medicine Business Overview
  52. 7.9.3 Hengrui Medicine Platinum-based Antineoplastic Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Hengrui Medicine Platinum-based Antineoplastic Product Portfolio
  54. 7.9.5 Hengrui Medicine Recent Developments
  55. 7.10 Hansoh Pharmaceutical Group
  56. 7.10.1 Hansoh Pharmaceutical Group Company Information
  57. 7.10.2 Hansoh Pharmaceutical Group Business Overview
  58. 7.10.3 Hansoh Pharmaceutical Group Platinum-based Antineoplastic Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Hansoh Pharmaceutical Group Platinum-based Antineoplastic Product Portfolio
  60. 7.10.5 Hansoh Pharmaceutical Group Recent Developments
  61. 7.11 GSK
  62. 7.11.1 GSK Company Information
  63. 7.11.2 GSK Business Overview
  64. 7.11.3 GSK Platinum-based Antineoplastic Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 GSK Platinum-based Antineoplastic Product Portfolio
  66. 7.11.5 GSK Recent Developments
  67. 7.12 Bristol-Myers Squibb
  68. 7.12.1 Bristol-Myers Squibb Company Information
  69. 7.12.2 Bristol-Myers Squibb Business Overview
  70. 7.12.3 Bristol-Myers Squibb Platinum-based Antineoplastic Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Bristol-Myers Squibb Platinum-based Antineoplastic Product Portfolio
  72. 7.12.5 Bristol-Myers Squibb Recent Developments
  73. 7.13 Abbvie
  74. 7.13.1 Abbvie Company Information
  75. 7.13.2 Abbvie Business Overview
  76. 7.13.3 Abbvie Platinum-based Antineoplastic Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Abbvie Platinum-based Antineoplastic Product Portfolio
  78. 7.13.5 Abbvie Recent Developments
  79. 7.14 AstraZeneca
  80. 7.14.1 AstraZeneca Company Information
  81. 7.14.2 AstraZeneca Business Overview
  82. 7.14.3 AstraZeneca Platinum-based Antineoplastic Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 AstraZeneca Platinum-based Antineoplastic Product Portfolio
  84. 7.14.5 AstraZeneca Recent Developments
  85. 7.15 Asta Medica GmbH
  86. 7.15.1 Asta Medica GmbH Company Information
  87. 7.15.2 Asta Medica GmbH Business Overview
  88. 7.15.3 Asta Medica GmbH Platinum-based Antineoplastic Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Asta Medica GmbH Platinum-based Antineoplastic Product Portfolio
  90. 7.15.5 Asta Medica GmbH Recent Developments
8 North America
  1. 8.1 North America Platinum-based Antineoplastic Market Size by Type
  2. 8.1.1 North America Platinum-based Antineoplastic Revenue by Type (2021-2032)
  3. 8.1.2 North America Platinum-based Antineoplastic Sales by Type (2021-2032)
  4. 8.1.3 North America Platinum-based Antineoplastic Price by Type (2021-2032)
  5. 8.2 North America Platinum-based Antineoplastic Market Size by Application
  6. 8.2.1 North America Platinum-based Antineoplastic Revenue by Application (2021-2032)
  7. 8.2.2 North America Platinum-based Antineoplastic Sales by Application (2021-2032)
  8. 8.2.3 North America Platinum-based Antineoplastic Price by Application (2021-2032)
  9. 8.3 North America Platinum-based Antineoplastic Market Size by Country
  10. 8.3.1 North America Platinum-based Antineoplastic Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Platinum-based Antineoplastic Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Platinum-based Antineoplastic Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe Platinum-based Antineoplastic Market Size by Type
  2. 9.1.1 Europe Platinum-based Antineoplastic Revenue by Type (2021-2032)
  3. 9.1.2 Europe Platinum-based Antineoplastic Sales by Type (2021-2032)
  4. 9.1.3 Europe Platinum-based Antineoplastic Price by Type (2021-2032)
  5. 9.2 Europe Platinum-based Antineoplastic Market Size by Application
  6. 9.2.1 Europe Platinum-based Antineoplastic Revenue by Application (2021-2032)
  7. 9.2.2 Europe Platinum-based Antineoplastic Sales by Application (2021-2032)
  8. 9.2.3 Europe Platinum-based Antineoplastic Price by Application (2021-2032)
  9. 9.3 Europe Platinum-based Antineoplastic Market Size by Country
  10. 9.3.1 Europe Platinum-based Antineoplastic Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Platinum-based Antineoplastic Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Platinum-based Antineoplastic Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
10 China
  1. 10.1 China Platinum-based Antineoplastic Market Size by Type
  2. 10.1.1 China Platinum-based Antineoplastic Revenue by Type (2021-2032)
  3. 10.1.2 China Platinum-based Antineoplastic Sales by Type (2021-2032)
  4. 10.1.3 China Platinum-based Antineoplastic Price by Type (2021-2032)
  5. 10.2 China Platinum-based Antineoplastic Market Size by Application
  6. 10.2.1 China Platinum-based Antineoplastic Revenue by Application (2021-2032)
  7. 10.2.2 China Platinum-based Antineoplastic Sales by Application (2021-2032)
  8. 10.2.3 China Platinum-based Antineoplastic Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Platinum-based Antineoplastic Market Size by Type
  2. 11.1.1 Asia Platinum-based Antineoplastic Revenue by Type (2021-2032)
  3. 11.1.2 Asia Platinum-based Antineoplastic Sales by Type (2021-2032)
  4. 11.1.3 Asia Platinum-based Antineoplastic Price by Type (2021-2032)
  5. 11.2 Asia Platinum-based Antineoplastic Market Size by Application
  6. 11.2.1 Asia Platinum-based Antineoplastic Revenue by Application (2021-2032)
  7. 11.2.2 Asia Platinum-based Antineoplastic Sales by Application (2021-2032)
  8. 11.2.3 Asia Platinum-based Antineoplastic Price by Application (2021-2032)
  9. 11.3 Asia Platinum-based Antineoplastic Market Size by Country
  10. 11.3.1 Asia Platinum-based Antineoplastic Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Platinum-based Antineoplastic Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Platinum-based Antineoplastic Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Platinum-based Antineoplastic Market Size by Type
  2. 12.1.1 SAMEA Platinum-based Antineoplastic Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Platinum-based Antineoplastic Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Platinum-based Antineoplastic Price by Type (2021-2032)
  5. 12.2 SAMEA Platinum-based Antineoplastic Market Size by Application
  6. 12.2.1 SAMEA Platinum-based Antineoplastic Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Platinum-based Antineoplastic Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Platinum-based Antineoplastic Price by Application (2021-2032)
  9. 12.3 SAMEA Platinum-based Antineoplastic Market Size by Country
  10. 12.3.1 SAMEA Platinum-based Antineoplastic Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Platinum-based Antineoplastic Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Platinum-based Antineoplastic Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Platinum-based Antineoplastic Value Chain Analysis
  2. 13.1.1 Platinum-based Antineoplastic Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Platinum-based Antineoplastic Production Mode & Process
  6. 13.2 Platinum-based Antineoplastic Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Platinum-based Antineoplastic Distributors
  9. 13.2.3 Platinum-based Antineoplastic Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst